Contrast Agents for Magnetic Resonance Imaging: Safety Update

Topics in Magnetic Resonance Imaging

Volumn 14, Issue 5, 2003, Pages 426-435

  Kirchin, Miles A ^a   Runge, Val M ^b  

^a Bracco Imaging SpA   (Italy)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Contrast media administration adverse effects; Gadolinium administration and adverse effects stability

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; IRON OXIDE; MANGAFODIPIR; MANGANESE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ABDOMINAL PAIN; BACKACHE; CARDIOTOXICITY; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; FLUSHING; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INJECTION SITE; LEG PAIN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; TASTE DISORDER; THERMODYNAMICS; URTICARIA;

CONTRAST MEDIA; DRUG STABILITY; GADOLINIUM; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MANGANESE; ORGANOMETALLIC COMPOUNDS; OXIDES;

EID: 0347504947     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002142-200310000-00007     Document Type: Review

References (73)

1. Runge VM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging. 2000;12:205-213.
2. Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging. 1999;10:477-484.
3. Runge VM. Safety of magnetic resonance contrast media. Top Magn Reson Imaging. 2001;12:309-314.
4. Niendorf HP, Kallend D. Gadolinium chelates: adverse reactions. In: Dawson P, Cosgrove DO, Grainger RG, eds. Textbook of Contrast Media. Oxford, UK: ISIS Medical Media, 1999;323-332.
5. Murphy KJ, Brunberg JA, Cohan RH. Adverse reactions to gadolinium contrast media: a review of 36 cases. AJR Am J Roentgenol. 1996;167: 847-849.
6. Goldstein HA, Kashanian FK, Blumetti R, et al. Safety assessment of Gd-DTPA in U.S. clinical trials. Radiology. 1990;174:17-23.
7. Niendorf HP, Haustein J, Cornelius I, et al. Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med. 1991;22:222-228.
8. Nelson KL, Gifford LM, Lauber-Huber C, et al. Clinical safety of Gd-DTPA. Radiology. 1995;196:439-443.
9. Olukotun AY, Parker JR, Meeks MJ, et al. Safety of gadoteridol injection: U.S. clinical trial experience. J Magn Reson Imaging. 1995;5:17-25.
10. Runge VM, Parker JR. Worldwide clinical safety assessment of gadoteridol injection: an update. Eur Radiol. 1997;7(suppl 5):243-245.
11. Aslanian V, Lemaignen H, Bunouf P, et al. Evaluation of the clinical safety of Gd-DTPA-BMA injection, a new nonionic MRI contrast medium for the central nervous system: a European perspective. Neuroradiology. 1996;38:537-541.
12. Rubin DL, Desser TS, Semelka R, et al. A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Gd-DTPA (Gd-DTPA) in patients with liver pathology: results of a phase III clinical trial. J Magn Reson Imaging. 1999;9:240-250.
13. Kirchin MA, Pirovano G, Venetianer C, et al. Safety assessment of gadobenate dimeglumine (Multihance®): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging. 2001;14:281-294.
14. Brown JJ, Kristy RM, Stevens GR, et al. The OptiMARK clinical development program: summary of safety data. J Magn Reson Imaging. 2002; 15:446-455.
15. Federle MP, Chezmar JL, Rubin DL, et al. Safety and efficacy of mangafodipir trisodium (Mn-DPDP) injection for hepatic MRI in adults: results of the U.S. multicenter Phase III clinical trials (safety). J Magn Reson Imaging. 2000;12:186-197.
16. Bluemke DA, Weber TM, Rubin DL, et al. Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol. Radiology. 2003;228:457-464.
17. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine. Acad Radiol. 1999;6:282-291.
18. Kirchin MA, Pirovano G, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol. 1998;33:798-809.
19. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. Invest Radiol. 1997;32:780-796.
20. de Haën C, Cabrini M, Akhnana L, et al. Gadobenate dimeglumine 0.5M solution for injection (MultiHance®): pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr. 1999;23(suppl 1):161-168.
21. Petersein J, Spinazzi A, Giovagnoni A, et al. Evaluation of the efficacy of gadobenate dimeglumine in MR imaging of focal liver lesions: a multicenter phase III clinical study. Radiology. 2000;215:727-736.
22. Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roentgenol. 2000; 175:1111-1120.
23. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphological and functional information from MR imaging with gadobenate dimeglumine. Radiology. 2001;221:731-739.
24. Colosimo C, Ruscalleda J, Korves M, et al. Detection of intracranial metastases: a multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol. 2001;36:72-81.
25. Runge VM, Armstrong MR, Barr RG, et al. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol. 2001;36:65-71.
26. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors: a bicentric intra-individual crossover comparison of gadobenate dimeglumine with gadopentetate dimeglumine for lesion enhancement. Radiology. 2004;(in press)
27. Völk M, Strotzer M, Lenhart M, et al. Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. Radiology. 2001;220:484-488.
28. Knopp MV, Schoenberg SO, Rehm C, et al. Assessment of gadobenate dimeglumine (Gd-BOPTA) for MR angiography: phase I studies. Invest Radiol. 2002;37:706-715.
29. Knopp MV, Giesel FL, von Tengg-Kobligk H, et al. Contrast-enhanced MR Angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging. 2003;17:694-702.
30. Tweedle M. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol. 1992;27(suppl 1):2-6.
31. Benner T, Reimer P, Erb G, et al. Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study. J Magn Reson Imaging. 2000;12:371-380.
32. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging. 1990;8:467-481.
33. Tweedle MF, Hagan JJ, Kumar K, et al. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging. 1991;9:409-415.
34. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol. 1995;30:372-380.
35. Puttagunta NR, Gibby WA, Smith GT. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol. 1996;31:739-742.
36. Corot C, Idee JM, Hentsch AM, et al. Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on zinc-dependent metallopeptidase angiotensin-converting enzyme. J Magn Reson Imaging. 1998;8:695-702.
37. Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology. 2003;227:630-646.
38. Normann PT, Froysa A, Svaland M. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. Scand J Clin Lab Invest. 1995;55:421-426.
39. Lin J, Idee J, Port M, et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. J Pharmaceutical Biomedical Analysis. 1999;21:931-943.
40. Omniscan (gadodiamide) injection package insert. Princeton, NJ: Nycomed Inc., 2000.
41. th ed. Washington, DC: American Association of Clinical Chemists, 2000.
42. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging. 1992;10:641-648.
43. Ekholm S, Jonsson E, Sandvik L, et al. Tolerance and efficacy on Omniscan (Gd-DTPA-BMA injection) in MR imaging of the central nervous system. Acta Radiol. 1996;37:223-228.
44. Haustein J, Laniado M, Niendorf H-P, et al. Triple dose versus standard-dose Gd-DTPA: a randomized study in 199 patients. Radiology. 1993; 186:855-860.
45. Brugières P, Gaston A, Degryse HR, et al. Randomized double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology. 1994;36:27-30.
46. Grossman RI, Rubin DI, Hunter G, et al. Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol. 2000;35:412-419.
47. Yuh WTC, Fisher DJ, Engelken JD, et al. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology. 1991;180:485-491.
48. Greco A, Parker JR, Ratcliffe CG, et al. Phase III, randomized, double blind, crossover comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol. 2001;45:457-463.
49. Myhr G, Rinck PA, Børseth A. Gadodiamide injection and gadopentetate dimeglumine: a double-blind study in MR imaging of the CNS. Acta Radiol. 1992;33:405-409.
50. Valk J, Algra PR, Hazenberg CJ, et al. A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology. 1993;35:173-177.
51. Åkeson P, Jonsson E, Haugen I, et al. Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology. 1995;37:229-233.
52. Oudkerk M, Sijens PE, van Beek EJ, et al. Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol. 1995;30:75-78.
53. Balériaux D, Matos C, De Greef D. Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA. Neuroradiology. 1993;35:490-494.
54. Knopp MV, Bourne MW, Sardanelli F, et al. Gadobenate dimeglumine in contrast-enhanced magnetic resonance imaging of the breast: a dose response analysis and comparison with gadopentetate dimeglumine. AJR Am J Roentgenol. 2003;181:663-676.
55. Runge VM, Bradley WG, Brant-Zawadzki MN, et al. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Radiology. 1991;181:701-799.
56. Sze G, Brant-Zawadzki MN, Haughton VM, et al. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology. 1991;181:693-699.
57. Swan SK, Lambrecht LJ, Townsend R, et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol. 1999;34:443-448.
58. Townsend RR, Cohen DL, Katholi R, et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. Am J Kidney Dis. 2000;36:1207-1212.
59. Davies BE, Kirchin MA, Bensel K, et al. Pharmacokinetics and safety of gadobenate dimeglumine (Multihance®) in subjects with impaired liver function. Invest Radiol. 2002;37:299-308.
60. Lalli AF. Urographic contrast media reactions and anxiety. Radiology. 1974;112:267-271.
61. Melendez JC, McCrank E. Anxiety-related reactions associated with magnetic resonance imaging examinations. JAMA. 1993;270:745-747.
62. Teslascan® (mangafodipir trisodium) injection: U.S. package insert. Princeton, NJ: Nycomed-Amersham, 1997.
63. Gallez B, Bacic G, Swartz HM. Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP. Magn Reson Med. 1996;35: 14-19.
64. Misselwitz B, Muhler A, Weinmann HJ. A toxicological risk for using manganese complexes? A literature survey of existing data through several medical specialties. Invest Radiol. 1995;30:611-620.
65. Hauser RA, Zesiewicz TA, Rosemurgy AS, et al. Manganese intoxication and chronic liver failure. Ann Neurol. 1994;36:871-875.
66. 2 and MnDPDP on the isolated and perfused rat heart. Invest Radiol. 1997;32:581-588.
67. Brurok H, Berg K, Sneen L, et al. Cardiac metal contents after infusions of manganese: an experimental evaluation in the isolated rat heart. Invest Radiol. 1999;34:470-476.
68. Fretz CJ, Elizondo G, Weissleder R, et al. Superparamagnetic iron oxide-enhanced MR imaging: pulse sequence optimization for detection of liver cancer. Radiology. 1989;172:393-397.
69. Reimer P, Kwong KK, Weisskoff R, et al. Dynamic signal intensity changes in liver with superparamagnetic MR contrast agents. J Magn Reson Imaging. 1992;2:177-181.
70. Oudkerk M, van den Heuvel AG, Wielopolski PA, et al. Hepatic lesions: detection with ferumoxide-enhanced T1-weighted MR imaging. Radiology. 1997;203:449-456.
71. Reimer P, Rummeny EJ, Daldrup HE, et al. Clinical results with Resovist: a phase II clinical trial. Radiology. 1995;195:489-496.
72. Ferridex IV® (ferumoxides injectable solution): U.S. package insert. Wayne, NJ: Berlex Laboratories, 1998.
73. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003;13:1266-1276.